For our April #radonc journal club we will discuss nonsurgical treatment of hepatocellular carcinoma, the most common liver cancer. Stereotactic body radiation therapy (SBRT) is an increasingly used approach to liver cancer, either as definitive treatment or a bridge to transplant. How does SBRT compare to radiofrequency ablation (RFA)?
Timely topic as the National Cancer Institute’s 2016 annual report shows liver cancer mortality is increasing in the U.S.
Our article is:
The article is temporarily free here starting April 20-24, thanks to the Journal of Clinical Oncology and ASCO.
The lead and senior authors, Dr. Daniel Wahl and Dr. Mary Feng of University of Michigan Medical Center, will join us to discuss at the live journal club Sunday April 24th at 8-9 PM Central Standard Time. We will focus on the following topics:
T1a. What is the role of nonsurgical local therapy for hepatocellular carcinoma, or liver cancer?
T1b. What are the biologic and technical differences in using RFA and SBRT?
T2. What were the aim and methods of this study?
T3. What were the results, and how do they compare to current standards for treatment delivery?
T4. What are the key questions for future research on SBRT for liver cancer?
We will start open chat 6 AM CST to include global participation. Moderator’s note: I’ll be flying part of the day, so please help me keep the conversation going!
- Here is the overview of how to participate
- Here is Twitter 101 for chat participation (except now just one day)
- Read our disclaimer for ways to keep it rewarding and professional. If you’re not ready, just lurk and tune into the conversation.
Any suggestions? Leave a comment or tweet us at @Rad_Nation. And please join us next weekend!